Scale-up of Kenya’s national HIV viral load program: Findings and lessons learned
暂无分享,去创建一个
M. Mwau | M. Sirengo | C. Boeke | Lucy Kithinji | L. Oyiengo | M. Adhiambo | Priska Bwana | Catherine Akinyi Syeunda | Joy Mwende
[1] R. Wanyenze,et al. Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014–July 2015 , 2017, BMC Infectious Diseases.
[2] J. Nkengasong,et al. Specimen origin, type and testing laboratory are linked to longer turnaround times for HIV viral load testing in Malawi , 2017, PloS one.
[3] J. Overbaugh,et al. Differences in virologic and immunologic response to antiretroviral therapy among HIV-1-infected infants and children , 2016, AIDS.
[4] J. Baeten,et al. HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy , 2016, Journal of acquired immune deficiency syndromes.
[5] Anthony K. Waruru,et al. Detectable HIV Viral Load in Kenya: Data from a Population-Based Survey , 2016, PloS one.
[6] S. Gregson,et al. Can Schools Support HIV/AIDS-Affected Children? Exploring the ‘Ethic of Care’ amongst Rural Zimbabwean Teachers , 2016, PLoS ONE.
[7] K. Bonner,et al. Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] S. Gregson,et al. It's harder for boys? Children's representations of their HIV/AIDS-affected peers in Zimbabwe , 2015, AIDS care.
[9] L. Cluver,et al. Factors associated with adherence to antiretroviral therapy among adolescents living with HIV/AIDS in low- and middle-income countries: a systematic review , 2015, AIDS care.
[10] R. Kosgei,et al. Factors Associated with Virological Failure and Suppression after Enhanced Adherence Counselling, in Children, Adolescents and Adults on Antiretroviral Therapy for HIV in Swaziland , 2015, PloS one.
[11] P. Lall,et al. Review: An urgent need for research on factors impacting adherence to and retention in care among HIV-positive youth and adolescents from key populations , 2015, Journal of the International AIDS Society.
[12] Patrick A Ryscavage,et al. Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review , 2015, Journal of the International AIDS Society.
[13] P. Goulder,et al. Immunity to HIV in Early Life , 2014, Front. Immunol..
[14] L. Muhe,et al. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age. , 2014, The Cochrane database of systematic reviews.
[15] S. Gregson,et al. Children’s representations of school support for HIV-affected peers in rural Zimbabwe , 2014, BMC Public Health.
[16] U. Liebert,et al. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children , 2014, BMC Infectious Diseases.
[17] B. Eley,et al. Improved virological suppression in children on antiretroviral treatment receiving community-based adherence support: A multicentre cohort study from South Africa , 2014, AIDS care.
[18] C. Hamilton,et al. Differences Between HIV-Infected Men and Women in Antiretroviral Therapy Outcomes — Six African Countries, 2004–2012 , 2013, MMWR. Morbidity and mortality weekly report.
[19] S. Urien,et al. Evaluation of nevirapine dosing recommendations in HIV-infected children. , 2013, British journal of clinical pharmacology.
[20] J. Elliott,et al. Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. , 2013, Bulletin of the World Health Organization.
[21] R. Greil,et al. Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals , 2009, Antiviral therapy.
[22] Ross J. Harris,et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. , 2009, International journal of epidemiology.
[23] A. Walker,et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study , 2006, BMJ : British Medical Journal.
[24] A. Geretti,et al. Comparative Evaluation of the Performance of the Abbott Real-Time Human Immunodeficiency Virus Type 1 (HIV-1) Assay for Measurement of HIV-1 Plasma Viral Load following Automated Specimen Preparation , 2006, Journal of Clinical Microbiology.
[25] J. Ioannidis,et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. , 1998, The New England journal of medicine.
[26] L. Kalish,et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. , 1997, The New England journal of medicine.
[27] Melbourne Victoria,et al. A Ministry of Health , 1917, Nature.